Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
4
First snow to fall in Seoul on Wednesday
-
5
Man convicted after binge eating to avoid military service
-
6
S. Korea not to attend Sado mine memorial: foreign ministry
-
7
Toxins at 622 times legal limit found in kids' clothes from Chinese platforms
-
8
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
9
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
10
[Weekender] Korea's traditional sauce culture gains global recognition
![[Weekender] Korea's traditional sauce culture gains global recognition](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
![[Weekender] Korea's traditional sauce culture gains global recognition](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050153_0.jpg&u=20241123224317)
CrystalGenomics appoint Gavin Choy as CEO of CG Pharmaceuticals
By Lim Jeong-yeoPublished : Oct. 8, 2020 - 15:04
CrystalGenomics on Thursday said it appointed Gavin Choy as the CEO of its US subsidiary, CG Pharmaceuticals.
Choy has 27 years of experience in researching and developing anticancer and antiviral treatments, as well as four successful clinical trial design applications with the US Food and Drug Administration, CrystalGenomics said.
At his new post, Choy will help CrystalGenomics advance its COVID-19 treatment pipeline for pancreatic cancer treatment research in the US.
Choy holds a doctorate in pharmacology from the University of Southern California. He has held roles as a clinical pharmacist at Stanford Health Care, clinical scientist at Gilead Sciences and vice president of Astex Pharmaceuticals, a US subsidiary of Otsuka Pharmaceutical.
Choy’s most recent position was at Apollomics, a cancer treatment development biotech, where he served as the chief operating officer since 2016.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
Choy has 27 years of experience in researching and developing anticancer and antiviral treatments, as well as four successful clinical trial design applications with the US Food and Drug Administration, CrystalGenomics said.
At his new post, Choy will help CrystalGenomics advance its COVID-19 treatment pipeline for pancreatic cancer treatment research in the US.
Choy holds a doctorate in pharmacology from the University of Southern California. He has held roles as a clinical pharmacist at Stanford Health Care, clinical scientist at Gilead Sciences and vice president of Astex Pharmaceuticals, a US subsidiary of Otsuka Pharmaceutical.
Choy’s most recent position was at Apollomics, a cancer treatment development biotech, where he served as the chief operating officer since 2016.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
![[More than APT] Residents, architects together design homes](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/24/20241124050036_0.jpg&u=)
